Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-AnalysisTao Li, Jiannan Yao, Haoning Lan et al.|Frontiers in Oncology|2021Cited by 12